Crizotinib in ALK-positive lung cancer

被引：4
|
作者：
Girard, Nicolas [1 ]
机构：
[1] Louis Pradel Hosp, F-69500 Bron, France
来源：
LANCET ONCOLOGY | 2012年 / 13卷 / 10期
关键词：
ANAPLASTIC LYMPHOMA; CELL; KINASE;
D O I：
10.1016/S1470-2045(12)70375-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：962 / 963
页数：2
相关论文
共 50 条
  • [21] Ensartinib vs crizotinib in ALK-positive NSCLC
    Venkatesan, Priya
    LANCET RESPIRATORY MEDICINE, 2020, 8 (10): : E76 - E76
  • [22] Use of crizotinib for refractory ALK-positive lymphomas
    Shelikhova, L. N.
    Fominykh, V. V.
    Abramov, D. S.
    Myakova, N. V.
    Maschan, M. A.
    Maschan, A. A.
    TERAPEVTICHESKII ARKHIV, 2017, 89 (07) : 51 - 56
  • [23] Brigatinib versus crizotinib for ALK-positive NSCLC
    Stirrups, Robert
    LANCET ONCOLOGY, 2018, 19 (11): : E585 - E585
  • [24] Advanced ALK-positive lung cancer with lorlatinib versus crizotinib in Asian patients with brain metastases
    Shih-Chang, Hung
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2023, 30 (01)
  • [25] Crizotinib: A New Treatment Option for ALK-Positive Non-Small Cell Lung Cancer
    O'Bryant, Cindy L.
    Wenger, Sarah D.
    Kim, Miryoung
    Thompson, Lisa A.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (02) : 189 - 197
  • [26] Combination ALK and MEK Inhibition in ALK-Positive Lung Cancer
    Ashton, J.
    Shrestha, N.
    Bland, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S857 - S857
  • [27] ALK-positive lung cancer: a moving target
    Jaime L. Schneider
    Jessica J. Lin
    Alice T. Shaw
    Nature Cancer, 2023, 4 : 330 - 343
  • [28] ALK-positive lung cancer: a moving target
    Schneider, Jaime L.
    Lin, Jessica J.
    Shaw, Alice T.
    NATURE CANCER, 2023, 4 (03) : 330 - 343
  • [29] Lorlatinib as a treatment for ALK-positive lung cancer
    Baba, Keisuke
    Goto, Yasushi
    FUTURE ONCOLOGY, 2022, 18 (24) : 2745 - 2766
  • [30] Emerging treatment for ALK-positive lung cancer
    Sharma, Janaki
    Pareek, Vipul
    Liu, Huijie
    Cheng, Haiying
    EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (02) : 147 - 155
12345